Current treatment options for idiopathic angioedema.
Document Type
Article
Publication Date
11-2015
Identifier
DOI: 10.1016/j.anai.2015.07.023
Abstract
BACKGROUND: Idiopathic angioedema is defined as localized swelling of the cutaneous and mucosal tissue that occurs in episodes without a clear etiology. It can be problematic to treat when the underlying pathophysiology is not well understood.
OBJECTIVE: To identify successful treatments of idiopathic angioedema reported in the literature.
METHODS: A literature search was performed using PubMed. Published case reports and articles discussing treatment of idiopathic angioedema were used in the formulation of this review. In addition, 2 case reports are provided.
RESULTS: Although there are no approved treatments for idiopathic angioedema, several medications used for the treatment of hereditary angioedema, such as bradykinin receptor antagonists (icatibant), kallikrein inhibitors (ecallantide), and C1 inhibitors, were successful in 10 patients. Anti-IgE monoclonal antibody (omalizumab) proved successful in 5 patients. The most widely used and successful medication was tranexamic acid (154 patients).
CONCLUSION: Despite an unknown etiology, this article highlights viable treatment options for idiopathic angioedema. More clinical trials and better markers identifying the cause of angioedema are needed.
Journal Title
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Volume
115
Issue
5
First Page
429
Last Page
433
MeSH Keywords
Adolescent; Angioedema; Antibodies, Anti-Idiotypic; Bradykinin; Female; Humans; Peptides; Tranexamic Acid
Keywords
Angioedema; Antibodies, Anti-Idiotypic; Bradykinin; Peptides; Tranexamic Acid
Recommended Citation
Shroba J, Hanson J, Portnoy J. Current treatment options for idiopathic angioedema. Ann Allergy Asthma Immunol. 2015;115(5):429-433. doi:10.1016/j.anai.2015.07.023
COinS
